
The tumour-targeting human L19-IL2 immunocytokine: preclinical …
Background: L19-IL2, a tumour-targeting immunocytokine composed of the recombinant human antibody fragment L19 (specific to the alternatively-spliced EDB domain of fibronectin, a well …
脑肿瘤治疗突破!抗体融合细胞因子:40%小鼠被治愈,临床试验 …
在这项研究中,研究人员在具有免疫功能的 神经胶质瘤 原位小鼠模型中测试了细胞因子IL-2、 IL-12 和TNF与抗体L19结合后(L19-IL2,L19-mTNF和L19-mIL12)的治疗效果(先前的研究表 …
The immunocytokine L19-IL2: An interplay between radiotherapy ... - PubMed
2018年1月16日 · Recently, we have shown that the administration of the tumour-targeted antibody-based immunocytokine L19-IL2 after radiotherapy (RT) resulted in synergistic anti …
A phase II study of the L19IL2 immunocytokine in combination …
Here we describe the results of a controlled, randomized phase II clinical trial, aimed at assessing the therapeutic potential of L19IL2, a fully human fusion protein consisting of the L19 antibody …
The immunocytokine L19-IL2: An interplay between radiotherapy …
The cytokine interleukin 2 (IL2) stimulates the proliferation and differentiation of cytotoxic, helper and regulatory T cells, and natural killer (NK) cells, resulting in a balanced pro- and anti …
The tumour-targeting human L19-IL2 immunocytokine: Preclinical …
2010年11月1日 · L19-IL2, a tumour-targeting immunocytokine composed of the recombinant human antibody fragment L19 (specific to the alternatively-spliced EDB domain of fibronectin, …
Intralesional administration of L19-IL2/L19-TNF in stage III or …
We recently reported that the intralesional injection of L19-IL2, an immunocytokine combining IL2 and the human monoclonal antibody fragment L19, resulted in efficient regional control of …
Full article: The immunocytokine L19-IL2: An interplay between ...
2018年1月16日 · Recently, we have shown that the administration of the tumour-targeted antibody-based immunocytokine L19-IL2 after radiotherapy (RT) resulted in synergistic anti …
The Immunocytokine L19–IL2 Eradicates Cancer When
2013年3月1日 · The immunocytokine L19–IL2, in which IL2 is fused to the human L19 antibody capable of selective accumulation on tumor neovasculature, has recently shown encouraging …
L19-IL2 Immunocytokine in Combination with the Anti-Syndecan …
L19-IL2 is an immunocytokine composed of an scFv specific for the angiogenesis-associated B-fibronectin (B-FN) isoform and IL2 (interleukin 2) selectively accumulated on tumor …